Certain commonly used compounds that interfere with the functions of the endocrine system are classified as endocrinedisrupting chemicals (EDCs). Bisphenol A (BPA) is an EDC that is widely used in food containers. BPA levels in human sera are commonly observed to be approximately 1-100 nM. Compared with the effects of BPA on the gonads, its effects on the adrenal gland are poorly understood. To investigate the influence of BPA on steroidogenesis, we examined the activity of the steroidogenic gene Cyp11a1 and its regulatory pathways in mouse Y1 adrenal cortex cells. Treatment with BPA at < 100 mM did not cause cell death. However, increased promoter activity and protein expression of Cyp11a1 were induced by low doses of BPA (10-1000 nM). Moreover, BPA induced c-Jun phosphorylation, and a specific inhibitor of c-Jun N-terminal kinase (JNK) significantly suppressed BPA-induced steroidogenesis. Thus, treatment of adrenal cells with low doses of BPA activated Cyp11a1 and increased corticosterone production through the JNK/c-Jun signaling pathway. Identical results were observed in rats after BPA injection. The abnormal induction of hormone synthesis by BPA in the adrenal gland might be linked to human metabolic defects and neuropsychiatric disorders.
abnormalities are associated with endocrine dysregulation and abnormal hormone production.
Because of the significant functions of hormones, their synthesis and metabolism require careful regulation. Steroidogenic enzymes encoded by the cytochrome P450 (Cyp) gene family catalyze the metabolism of cholesterol to form steroid hormones (Guse-Behling et al., 1992) . The first and rate-limiting step of steroidogenesis is catalyzed by the cholesterol side-chain cleavage enzyme cytochrome P450scc, which is encoded by Cyp11a1. This gene has high expression levels in steroid-producing tissues, such as the gonads, placenta, and adrenal cortex. It is well known that Cyp11a1 expression is under the control of steroidogenic factor 1 (SF-1), also named NR5A1. There are also other regulatory elements in the promoter region of Cyp11a1, such as AP-1 (Guo et al., 2007; , which is the conserved binding sequence for the Jun/Fos family of transcription factors. However, no studies have been conducted on the regulation of the Cyp11a1 promoter after BPA stimulation.
In terms of its mechanism of action, BPA has only 10 À4 -10 À3 times the estrogen receptor (ER) binding affinity as estradiol (Gould et al., 1998) . Thus, only high dose exposure to BPA can affect the functions of natural ER ligands, such as estrogens. However, the detectable concentrations and potentially harmful levels of BPA in human tissues are in the nanomolar to micromolar range (Eng et al., 2013; Vandenberg et al., 2007) . Therefore, some studies have investigated the involvement of G proteincoupled receptors (GPRs) and related signaling pathways in the mechanism of action of BPA (Kim et al., 2010; Sheng et al., 2013) . BPA can stimulate the MAPK signaling pathway and has been shown to induce gene expression and tumor proliferation through GPR30 in cancer cells (Dong et al., 2011) . It is also known that BPA can induce protein kinase A (PKA) and Akt activation in testicular Leydig cells (Kim et al., 2010) . In human granulosa cells, BPA was shown to induce peroxisome proliferator-activated receptor gamma (PPARc) and to downregulate FSH-stimulated steroidogenesis and proliferation via the activation of GATA sequence-binding transcription factors (Kwintkiewicz et al., 2010) . Furthermore, the Pten/Akt signaling pathway was shown to participate in BPA-induced apoptosis of rat Sertoli cells (Wang et al., 2015) . Exposure to BPA-induced dysfunction of insulin secretion and increased apoptosis in rat insulinoma cells through mitochondrial damage (Lin et al., 2013) . In summary, BPA has been shown to be involved in cell proliferation, apoptosis, and steroidogenesis through various receptors and/or signaling pathways in various cell models.
Compared with studies of the effects of BPA on the gonads, fewer studies exist on its effects on the adrenal gland. The adrenal glands secrete glucocorticoids and play an important role in the stress response and metabolism. Recent studies have shown that some metabolic syndromes (Eng et al., 2013) and disorders of the Hypothalamic-pituitary-adrenal axis may be correlated with BPA exposure . Therefore, we considered whether BPA influences adrenal hormone production. It is well established that the first and rate-limiting step of steroidogenesis is catalyzed by P450scc, which is encoded by Cyp11a1 in the adrenal glands and that the steroid hormone biosynthesis pathway may be the target of BPA (Sanderson, 2006) . In this study, we investigated hormone production and steroidogenic gene activity in response to low-dose BPA. We detected Cyp11a1 expression, corticosterone secretion, and stimulated signaling after BPA treatment in Y1 cells. Y1 is a mouse adrenocortical tumor cell line, and Y1 cells produce glucocorticoids and are used as an endocrine study model (Schimmer, 1995) . We also used SD rats as an in vivo model to confirm the BPA effects and the regulatory mechanisms of those effects observed in Y1 cells. According to our findings, BPA at concentrations below the micromolar (mM) level affect adrenal cell signaling, gene expression, and hormone production.
MATERIALS AND METHODS
Cell culture and reagents. Y1 cells, a mouse adrenocortical tumor cell line (ATCC CCL-79), were used as a steroidogenic study model and were maintained in Dulbecco's modified Eagle's medium (DMEM) supplemented with 10% fetal calf serum and penicillin/streptomycin. As a positive control, 1 mM 8-Br-cAMP (Sigma-Aldrich) was added to Y1 cells for 24 h. BPA (SigmaAldrich) was dissolved in methanol and added to the cell cultures at suitable concentrations (1-1000 nM) for 24-96 h for the stimulation experiments. Only methanol was added to the control cells, and the final concentration of methanol was lower than 1% in all experiments. Twenty-five micromolar SP600125 (Calbiochem), an inhibitor of Jun N-terminal kinase (JNK), was used to block-specific signals in Y1 cells for 24 hours.
Cell viability assay. The MTT assay, which is a colorimetric assay, was used to measure cell viability. Thiazolyl blue tetrazolium bromide (MTT) (Sigma-Aldrich) was prepared in PBS buffer (5 mg/ml) and stored at 4 C. The MTT stock solution was diluted to 1 mg/ml in DMEM serum-free medium before use. Y1 cells were seeded in 24-well plates and incubated overnight. BPA was then added to the medium at the indicated concentrations (0-200 mM) for the indicated time periods (0-96 h). After BPA treatment, the medium was removed, 200 ml MTT solution/well was added at 37 C, and the plates were incubated for 2 h. Then, 200 ml of dimethyl sulfoxide was added to each well, and the plates were shaken for 5 min to the dissolve crystals. The final results were read using a microplate reader at a wavelength of 450 nm.
Plasmid transfection and reporter assays. The 2.3-kb luciferaseexpressing plasmid Cyp11a1-Luc, which contained AP-1 and SF-1 binding sites, was used as previously described (Huang et al., 2001) . Y1 cells were transfected in vitro using Lipofectamine 2000 (Invitrogen Life Technologies) or TurboFect (Fermentas), according to the manufacturers' recommended procedures. Cells were harvested in lysis buffer (100 mM potassium phosphate, pH 7.8; 0.2% Triton X-100; 0.5 mM dithiothreitol; and 0.2 mM phenylmethylsulfonyl fluoride) at 24-48 h after transfection and subjected to luciferase assays using a Dual-Luciferase Reporter Assay System (Promega). All reporter luciferase levels were normalized against pRluc-regulated Renilla luciferase as the transfection control, and the value of the Cyp11a1-Luc reporter result was set at 1.0 for the data calculation and presentation.
Western blotting and antibodies. Treated cells were harvested and lysed in lysis buffer as described above or placed directly in sodium dodecyl sulfate gel loading buffer with detergent. Equal amounts of whole cell extracts were loaded and separated by gel electrophoresis and then transferred to Immobilon-P-membranes (Millipore). The membranes were incubated with anti-CYP11A1 (Hu et al., 1999) , anti-c-Jun (sc-45, Santa Cruz Biotechnology Inc.), anti-phospho-c-Jun (sc-822, Santa Cruz Biotechnology Inc.), anti-SF-1 , or antib-actin antibody (GTX109639, GeneTex) overnight at 4 C and then incubated with a horseradish peroxidase HRP-conjugated secondary antibody for 1 h. Signals were developed using ECL Western blotting reagents and detected using autoradiography films.
Enzyme-linked immunosorbent assay. Culture medium from Y1 cells was collected before the cells were harvested and saved in 1.5 ml tubes at À80 C. An enzyme-linked immunosorbent assay (ELISA) kit (#500655; Cayman Chemical) was used to determine the corticosterone levels in the media samples. A standard curve was generated using the provided reference standard dissolved in DMEM. All samples were measured according to the instructions accompanying the kits. The results were read using a microplate reader (Luminescence Scanner, Thermo Scientific Fisher Inc.) at a wavelength of 450 nm. Hormone concentrations were calculated based on the standard curve and are presented in pg/ml.
Animal treatments. This study focused on the HPA axis and the endocrine response to BPA; therefore, several organs of the animals needed to be kept for future studies. Due to concerns regarding the convenience of tissue collection, we used a rat
in vivo model instead of a mouse in vivo model. We referred to a previous study for the methods of the animal experiments . Male SD rats (8 weeks old) were used for this study and were housed individually at the NDMC (National Defense Medical Center) animal center under a regular light cycle (12 h light/12 h dark) at room temperature (24 6 2 C) with normal chow and tap water provided. Blood samples were collected from the tail vein on the second day after arrival (before injection, basal measurement) and the day before sacrifice (after injection, treated measurement). For the treatment group, BPA (Sigma-Aldrich) was dissolved in sesame oil and subcutaneously injected at 0.5 mg/kg body weight/day for 3 days (days 3-5 after arrival) (n ¼ 12). The control group was injected with sesame oil alone following the same procedure (n ¼ 6). All animals were sacrificed at day 6, and tissue extracts from the adrenal glands were collected for protein analysis. All procedures for the animal experiments were performed following the 3Rs principles (replacement, reduction, and refinement) and were supervised by the IACUC (Institutional Animal Care and Use Committee) at the NDMC. The applications for the animal experiments passed the audit of the IACUC, and the approval number is IACUC-14-017.
RESULTS

Low Concentrations and Prolonged Exposure to BPA Did Not Affect Y1 Cell Viability
We first investigated the toxicity of BPA against Y1 cells. A MTT assay was performed to determine cell viability after stimulation. Cell viability was reduced significantly by 150-200 mM BPA, but the Y1 cells grew normally at BPA concentrations below 100 mM (Fig. 1A) . The lower panel in Figure 1A shows reduced expression of the housekeeping gene b-actin in the presence of ! 100 mM BPA. To confirm the long-term effects of BPA, we further examined cell viability after treatment with lower BPA concentrations (10 nM-1 mM) for 48-96 h, and no effects of BPA on the cells were observed in those studies (Fig. 1B) . The amount of b-actin present in the cells was similar under all experimental conditions (Fig. 1B, lower panel) . According to these results, the normally detectable levels of BPA in human serum (0.1-1000 nM) did not affect Y1 cell viability; thus, these concentrations were used in the following experiments.
Low Doses of BPA Enhanced CYP11A1 Protein Expression and Corticosterone Production Y1 cell culture medium supernatant was collected for hormone analysis. The corticosterone level was significantly enhanced by BPA treatment (Fig. 2A) . We further investigated the protein level of the steroidogenic enzyme CYP11A1, which catalyzes the first and rate-limiting step of steroidogenesis. CYP11A1 was significantly upregulated with increasing BPA concentrations ( Fig.  2B ) and stimulation times (Fig. 2C ). We used 1 mM 8-Br-cAMP treatment as the positive control (Fig. 2C, lane 2) . We found elevated corticosterone production and CYP11A1 expression following treatment with low concentrations of BPA.
BPA-Activated Cyp11a1 Gene Expression
Cyp11a1 promoter activity was measured to determine Cyp11a1 transcriptional activity. The upper panel in Figure 3A shows the AP-1 and SF-1 binding sites of the natural Cyp11a1 promoter (Huang et al., 2001) . Compared with reporter treatment alone, stimulation with BPA at 50-1000 nM enhanced promoter activity significantly (2-to 3-fold). Stimulation with 8-Br-cAMP alone is a well-defined positive control for this system (Lan et al., 2012) . We further examined Cyp11a1 promoter activity with combined BPA and 8-Br-cAMP treatments, and greater Cyp11a1 activation was observed than with either treatment alone (Fig. 3B) . We examined the effects of 100 nM BPA and higher BPA concentrations (10 3 and 10 4 nM) combined with cAMP on Cyp11a1 promoter activity ( Supplementary Fig. 1 ). No significant increase in Cyp11a1 promoter activity was observed with BPA treatment at concentrations over 100 nM; however. cotreatment of BPA and cAMP showed increased Cyp11a1 promoter activity. Thus, when more BPA cannot activate the Cyp11a1 promoter, the addition of cAMP further increased Cyp11a1 promoter activity. This suggests that although BPA and 8-Br-cAMP can both activate Cyp11a1, they might stimulate the gene in different ways.
C-Jun Phosphorylation, but Not SF-1 Level, Is Correlated With the Activation of CYP11A1 Expression by BPA According to previous data, BPA treatment enhances the transcription of steroidogenic genes; thus, we further studied the factors that regulate this effect. As shown in Figure 2 , CYP11A1 expression was obviously enhanced by BPA stimulation in dose- (Fig. 4A ) and time-dependent (Fig. 4B ) manners. However, the protein amount of the transcription factor SF-1 was not altered by BPA treatment. After quantification of the protein signals, we found that the phosphorylation level of c-Jun and the level of CYP11A1 were increased by BPA treatment (Fig. 4A and 4B right panel). Treatment with 8-Br-cAMP was used as the positive control and enhanced both CYP11A1 expression and cJun phosphorylation. The total amount of c-Jun protein was not affected, implying that the effects of BPA treatment involved posttranslational modification of c-Jun.
BPA-Induced Activation of Steroidogenesis Was Blocked by JNK Inhibitor
We found that the level of phosphorylated c-Jun (phospho-cJun) was positively correlated with the increase in CYP11A1 expression induced by BPA treatment. Next, we used the JNK-specific inhibitor SP600125 to block the c-Jun signaling pathway. The promoter activity of Cyp11a1 was enhanced by BPA treatment, similar to the previous experiments, but the JNK-specific inhibitor disrupted this stimulation (Fig. 5A ).
Immunoblotting revealed significantly reduced levels of both CYP11A1 and phospho-c-Jun in the presence of the inhibitor (Fig. 5B) . Treatment with SP600125 also reduced the BPAinduced corticosterone production (Fig. 5C ). These results indicate that the increase in steroidogenic gene expression and the consequent increase in corticosteroid release caused by BPA treatment were mediated by the JNK/c-Jun signaling pathway.
BPA-Induced Corticosterone Levels and the Expression of Steroidogenic Genes in Rats
To confirm that the regulatory pathway of steroidogenic genes that was affected by BPA treatment in Y1 cells is also present in vivo, we detected the response of rats to BPA treatment. A significantly higher corticosterone level was found in rat serum after 0.5 mg/kg BPA injection compared with injection of solvent alone and compared with the basal serum sample before injection (Fig. 6A ). Protein expression in the adrenal cortex of these rats was analyzed, and the levels of CYP11A1 and phospho-c-Jun were enhanced by BPA treatment in vivo. These results indicate that the regulation pathway of steroidogenic gene expression this is affected by BPA treatment exists in both Y1 cells and normal rat adrenal cells.
Summary of Results
In summary, we found that adrenal Y1 cells maintained their viability after exposure to nanomolar levels of BPA; however, Cyp11a1 expression was changed via c-Jun phosphorylation through activation of JNK signaling. Furthermore, this effect of BPA was blocked by the JNK-specific inhibitor SP600125. Once the signaling pathway had been activated by BPA, the Cyp11a1 promoter was stimulated, leading to increased Cyp11a1 gene expression and corticosterone production (Fig. 7) .
DISCUSSION
Influences of BPA in Steroidogenesis
In this study, we demonstrated that JNK/c-Jun signaling is important for the activation of steroidogenesis by BPA in adrenocortical cells. Our results are consistent with those of previous studies. Kim et al. (2010) showed that BPA treatment (0.1-10 nM for 24 h) upregulated the aromatase enzyme CYP19 in rat Leydig cells. In granulosa cells, BPA (0.1-10 mM for 48 h) increased progesterone secretion and Cyp11a1 expression (Zhou et al., 2008 ). An animal study also showed increased hormone production and Cyp11a1 gene expression in the mouse urogenital sinus after BPA treatment at 20 mg/kg body weight (Arase et al., 2011) . Similar to the findings of this study, the results of these previous studies indicate that BPA can activate steroidogenesis. However, the results of another study indicated that BPA treatment at 10-100 mg/ml (50-500 mM) suppressed hormone synthesis and inhibited steroidogenesis through the downregulation of Cyp11a1 expression in cultured mouse antral follicles (Peretz and Flaws, 2013) . Additionally, BPA treatment at 2.4 mg/ kg suppressed aromatase expression and estradiol synthesis in rat Leydig cells (Akingbemi et al., 2004) . These conflicting results may be due to differences in experimental approaches, including the use of different animal species, cell types, treatment procedures, and BPA dosages.
BPA Effects on the Adrenal Gland Function
The effects of BPA on the adrenal gland have also been studied. BPA at concentrations of 300-3000 ng/ml (1.5-15 mM) significantly disrupted steroidogenesis in human adrenal H295R cells (Zhang et al., 2011) . Furthermore, BPA treatment (1-100 mM) was shown to inhibit the expression of the norepinephrine transporter in cultured bovine adrenal medullary cells (Toyohira et al., 2003) . These results indicate that BPA suppresses adrenal function, which contradicts the findings of this study. We assume that differences in the BPA concentrations used might explain these conflicting results, as the concentrations used in the previous studies were 10-100 times higher than those used in our study. Accordingly, it seems that adrenal function is activated by BPA at micromolar concentrations but is suppressed at concentrations over 1 mM. Furthermore, nanomolar dosages of BPA more accurately represent the serum concentrations of BPA expected to be found in the general population (Teeguarden and Hanson-Drury, 2013) . Our data showed a significant effect of BPA at concentrations of 50-1000 nM (Figs. 2-4) , which are slightly higher than the detectable concentrations of BPA in the serum. However, long-term treatment with 10 nM BPA generated similar effects to short-term treatments with 50-1000 nM BPA (Figs. 2B and 4B ). We believe that the concentrations of BPA used in this study reflect physiological conditions because hydrophobic compounds, such as BPA, have higher accumulation in the adrenal glands than in the serum. Other studies also revealed significant induction of gene expression and enhancement of cell proliferation at this BPA concentration range (1-1000 nM) (Ge et al., 2014; Sheng et al., 2013) . Thus, similar to the results of our study, BPA can influence the body at low concentrations through daily life exposure. Of note, in January 2015, the European Food Safety Authority (EFSA) decreased the safe level of BPA exposure from 50 mg/kg of body weight (bw)/day to 4 mg/kg.bw/day. However, our results indicate that a BPA dosage of 0.5 mg kg.bw/day can activate CYP11A1 expression and increase corticosterone level in rats (Fig. 6) . 
Signaling Pathway of BPA
Previous studies demonstrated that a low dose of BPA activated the ERK signaling pathway and gene expression via GPRs during cancer cell proliferation (Ge et al., 2014; Sheng et al., 2013) . It is also known that BPA treatment can induce the activation of PKA and Akt in testicular Leydig cells (Kim et al., 2010) and that the expression of CREB is enhanced by BPA treatment (Bouskine et al., 2009) . Furthermore, the JNK and p53 signaling pathways participate in cell apoptosis and gene expression and are regulated by BPA . c-Jun phosphorylation has also been mentioned in some studies of the effects of BPA. BPA induces apoptosis through the JNK/p38 MAPK pathway in rat Sertoli cells (Qi et al., 2014) . BPA also induces apoptosis through reactive oxygen species, MAPK, and NF-kB in hippocampal neuronal cells (Lee et al., 2008) . Few studies have discussed JNK/c-Jun signaling in the adrenal gland under BPA stimulation. However, it is well known that c-Jun phosphorylation is important for Cyp11a1 expression in adrenal cells , and this is the first paper to demonstrate that BPA induces c-Jun phosphorylation. We could not conclude whether other factors in addition to c-Jun are activated by BPA in this study. Other signaling molecules that could be affected by BPA, such as CREB and ERK, need to be investigated.
Compare the Effects of cAMP and BPA
In the stimulation experiments, we demonstrated that both BPA and 8-Br-cAMP upregulated c-Jun phosphorylation and Cyp11a1 expression (Figs. 3 and 4B) . However, we believe that the mechanisms of this upregulation by BPA and 8-Br-cAMP are not identical, based on the observation of greater activation with the combined treatment of these 2 molecules ( Fig. 3B and Supplementary Fig. 1 ). It is well known that treatment with cAMP upregulates the downstream signaling molecules CREB and c-Jun to control gene expression in adrenal cells (Forti et al., 2006; Lan et al., 2007) . Studies of the mechanism of action of BPA have shown that multiple signaling pathways are involved. For example, Ca2þ signaling, phosphoinositide-3 kinase and ER are involved in the effects of BPA in the pituitary cell line GH3/B6/ F10 (Bulayeva and Watson, 2004) . Low doses of BPA promote human seminoma cell proliferation by activating PKA and PKG (Bouskine et al., 2009) . These results show that BPA stimulates some signals that are also stimulated by cAMP and some that are not stimulated by cAMP. This implies that both BPA and cAMP have multiple effects on cell signaling; therefore, we suggest that the functions of BPA are somewhat distinct from those of cAMP.
Regulation of Transcription Factors
In terms of the regulation of transcription factors, we found that the total protein content of SF-1 was not altered by BPA treatment (Fig. 4) , which was consistent with a previous study in granulosa cells (Kwintkiewicz et al., 2010) . However, the posttranslational modification of SF-1 was not investigated in our study. It is well known that the MAPK signaling pathway activates SF-1 by phosphorylating it at Ser-203 (Hammer et al., 1999) . Additionally, the herbicide atrazine was shown to enhance SF-1 phosphorylation and Cyp11a1 expression in placental JEG-3 cells (Suzawa and Ingraham, 2008) . In addition to SF-1, PPAR-c is a target of EDCs (Riu et al., 2011) . Additionally, EDCs promote adipogenesis in 3T3-L1 cells through glucocorticoid receptor activation (Sargis et al., 2010) . Thus, it is possible that BPA activates steroidogenic genes not only through c-Jun signaling but also through posttranslational modifications of SF-1 or other transcription factors.
Physiological Disorders and BPA
This study demonstrated that low doses (10-1000 nM) of BPA enhanced c-Jun phosphorylation and CYP11A1 expression levels, thereby, enhancing corticosterone production in the adrenal gland. Recent studies also showed that rat perinatal exposure to low-dose BPA led to abnormal adrenal histology, including increased adrenal weight and hyperplasia of the corticosteroidproducing zone (zona fasciculata) (Panagiotidou et al., 2014) , due to the production of abundant corticosteroids. This is consistent with our findings that low-dose BPA exposure causes higher levels of corticosteroids in the body. Corticosteroids are involved in a wide range of physiological functions, including stress and immune responses, metabolism and neuronal function. There is increasing concern that BPA might cause neurological damage (Kajta and Wojtowicz, 2013) and may be correlated with metabolic syndrome (Eng et al., 2013; Sargis et al., 2010) . However, the influence of BPA on the adrenal gland has not been thoroughly investigated. Although there is some evidence that BPA affects the HPA axis Panagiotidou et al., 2014; Poimenova et al., 2010) , no studies have examined steroidogenic gene regulation by BPA in the adrenal gland. Here, we showed that BPA exposure was significantly implicated in corticosterone release. Increased levels of corticosterone in the body can induce negative feedback control of the HPA axis and cause serious side effects, including metabolic defects and neuropsychiatric disorders. 
